Notable Guests
OK
Omkar Kawalekar
2x
ZZ
Zoe Zheng
2x
AB
Annette Bakker
1x
BS
Brian Sullivan
1x
CR
Cyriac Roeding
1x
DC
David Craig
1x
ET
Elizabeth Trentacost
1x
EW
EA Weeks
1x
ET
Eva Temkin
1x
JL
Jeremy Levin
1x
JY
Jhong-Jhe You
1x
JK
Johanna Kaufmann
1x
JR
Jonathan Rigby
1x
KK
Kat Kozyrytska
1x
AB
Aris Baras
1x
Recent Episodes
✨
Simeon George discusses SR One's biotech investment evaluation process and diligence signs.
Simeon George, M.D
Advancing Cell Therapy Toward a Functional Cure for T1D With BetaNova's Jonathan Rigby and Will Rust
✨
Sernova and Seraxis merge to form BetaNova, aiming for T1D functional cure.
Jonathan Rigby
Will Rust
✨
Tonix Pharmaceuticals builds a flexible vaccine manufacturing facility in Dartmouth, MA.
Siobhan Fogarty
✨
Earli uses bioAI, synthetic DNA, and nanoparticles to reprogram cancer cells into immune therapy factories.
✨
Philina Lee discusses lead-based targeted alpha therapies for deeper cancer responses.
Philina Lee, Ph.D
✨
CGT deals need new structures due to layered IP and complex manufacturing.
EA Weeks
✨
Former FDA staffers discuss 2026 regulatory updates.
Elizabeth Trentacost
Eva Temkin
✨
Alex Aravanis discusses obesity opportunities beyond GLP-1s.
Alex Aravanis, M.D., Ph.D
✨
Allan Shaw discusses current biotech financing and capital acquisition strategies.
✨
Roche's Sylke Poehling discusses selecting drug modalities based on disease biology.
Sylke Poehling, Ph.D
✨
Discussed cell and gene therapy manufacturing challenges with Tatyana Matveeva, Ph.D.
✨
David Craig discusses building a virtual biotech without institutional capital.
✨
Olivier Litzka discusses attracting capital and surviving biotech challenges.
✨
Autoimmune CAR T therapy is advancing rapidly, requiring a new patient-focused strategy.
Panteli Theocharous
✨
Deck Bio's multi-peptide-MHC-targeted T-cell engagers aim to treat solid tumors.
✨
Santé Ventures focuses on funding early-stage biotech with clinical data and differentiation.
✨
Brian Sullivan shares Celcuity's first FDA approval for Revtorpyk.
✨
Sonal Gupta discusses engineering regulatory T cells for solid tumors.
✨
Nathalie Clément addresses historical challenges in AAV vector purification.
✨
Paul Hastings discusses building allogeneic CAR NK cell therapies.